Paediatric Diseases Working Party (PDWP)
Study type:
Study number:
8417027
Type of Stem Cell Treatment:
Allogeneic - Haploidentical
Diseases:
Acute Lymphatic Leukaemia (ALL)
Acute Myeloid Leukaemia (AML)
Short title:
PT-Cy based haploidentical HSCT for Acute Leukemia
Primary objective:
Primary end point:
Leukemia-free survival (LFS)
Secondary end points are:
Haematopoietic recovery, grades II-IV and grade III-IV GVHD, chronic GVHD, transplantation-related mortality, relapse, GRFS and OS
Leukemia-free survival (LFS)
Secondary end points are:
Haematopoietic recovery, grades II-IV and grade III-IV GVHD, chronic GVHD, transplantation-related mortality, relapse, GRFS and OS
Key inclusion criteria:
1) Patient age less/= than 18 years
2) Patient diagnosed with either ALL or AML
3) Patient who underwent a first allograft between 2010 and 2016 included.
4) Patient which received unmanipulated (non TCD) haploidentical stem cell transplantation
5) Post-transplant cyclophosphamide as GVHD prophylaxis
2) Patient diagnosed with either ALL or AML
3) Patient who underwent a first allograft between 2010 and 2016 included.
4) Patient which received unmanipulated (non TCD) haploidentical stem cell transplantation
5) Post-transplant cyclophosphamide as GVHD prophylaxis
Country:
Italy
Principal investigator:
Annalisa Ruggeri
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email:
arnaud.dalissier@upmc.fr